Enanta Pharmaceuticals ENTA Stock
Enanta Pharmaceuticals Price Chart
Enanta Pharmaceuticals ENTA Financial and Trading Overview
| Enanta Pharmaceuticals stock price | 13.23 USD |
| Previous Close | 13.7 USD |
| Open | 13.43 USD |
| Bid | 9.88 USD x 200 |
| Ask | 17.25 USD x 200 |
| Day's Range | 13.43 - 13.97 USD |
| 52 Week Range | 6.44 - 17.15 USD |
| Volume | 132.47K USD |
| Avg. Volume | 212.13K USD |
| Market Cap | 396.63M USD |
| Beta (5Y Monthly) | 0.967 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.17 USD |
ENTA Valuation Measures
| Enterprise Value | 419.47M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.6601562 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.730558 |
| Price/Book (mrq) | 3.3998005 |
| Enterprise Value/Revenue | 6.061 |
| Enterprise Value/EBITDA | -7.565 |
Trading Information
Enanta Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.967 |
| 52-Week Change | 106.98% |
| S&P500 52-Week Change | 20.36% |
| 52 Week High | 17.15 USD |
| 52 Week Low | 6.44 USD |
| 50-Day Moving Average | 13.47 USD |
| 200-Day Moving Average | 13.15 USD |
ENTA Share Statistics
| Avg. Volume (3 month) | 212.13K USD |
| Avg. Daily Volume (10-Days) | 232.82K USD |
| Shares Outstanding | 29.08M |
| Float | 20.06M |
| Short Ratio | 10.17 |
| % Held by Insiders | 4.68% |
| % Held by Institutions | 92.73% |
| Shares Short | 2.58M |
| Short % of Float | 10.64% |
| Short % of Shares Outstanding | 8.88% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | September 30, 2026 |
Profitability
| Profit Margin | -89.55% |
| Operating Margin (ttm) | -69.071% |
| Gross Margin | 100.00% |
| EBITDA Margin | -80.11% |
Management Effectiveness
| Return on Assets (ttm) | -11.83% |
| Return on Equity (ttm) | -58.99% |
Income Statement
| Revenue (ttm) | 69.21M USD |
| Revenue Per Share (ttm) | 2.75 USD |
| Quarterly Revenue Growth (yoy) | 15.00% |
| Gross Profit (ttm) | 69.21M USD |
| EBITDA | -55451000 USD |
| Net Income Avi to Common (ttm) | -61984000 USD |
| Diluted EPS (ttm) | -2.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 163.77M USD |
| Total Cash Per Share (mrq) | 5.63 USD |
| Total Debt (mrq) | 186.62M USD |
| Total Debt/Equity (mrq) | 160.07 USD |
| Current Ratio (mrq) | 3.842 |
| Book Value Per Share (mrq) | 4.012 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7838000 USD |
| Levered Free Cash Flow (ttm) | 7.69M USD |
Profile of Enanta Pharmaceuticals
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 4 Kingsbury Avenue |
| ZIP | 02472 |
| Phone | 617 607 0800 |
| Website | https://www.enanta.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 120 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Q&A For Enanta Pharmaceuticals Stock
What is a current ENTA stock price?
Enanta Pharmaceuticals ENTA stock price today per share is 13.23 USD.
How to purchase Enanta Pharmaceuticals stock?
You can buy ENTA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Enanta Pharmaceuticals?
The stock symbol or ticker of Enanta Pharmaceuticals is ENTA.
Which industry does the Enanta Pharmaceuticals company belong to?
The Enanta Pharmaceuticals industry is Biotechnology.
How many shares does Enanta Pharmaceuticals have in circulation?
The max supply of Enanta Pharmaceuticals shares is 29.08M.
What is Enanta Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Enanta Pharmaceuticals PE Ratio is now.
What was Enanta Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Enanta Pharmaceuticals EPS is -2.6 USD over the trailing 12 months.
Which sector does the Enanta Pharmaceuticals company belong to?
The Enanta Pharmaceuticals sector is Healthcare.
Enanta Pharmaceuticals ENTA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26269.23 USD — |
+0.62
|
6.33B USD — | 26041.13 USD — | 26316.81 USD — | — - | 6.33B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12896.68 USD — |
+0.63
|
— — | 12785.35 USD — | 12920.04 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6562.03 USD — |
+0.7
|
— — | 6454.97 USD — | 6563.4 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1251.97 USD — |
+0.86
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32406.63 USD — |
+0.62
|
— — | 32125.24 USD — | 32465.34 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7161.62 USD — |
+0.7
|
— — | 7044.78 USD — | 7163.12 USD — | — - | — — |
- {{ link.label }} {{link}}